Biosion’s SynAb™ technology allows for the discovery of synergistic antibody combinations of two or more monoclonal antibodies to the same drug target, thus achieving maximal clinical efficacy by fully modulating (activating or inhibiting) drug target-mediated disease-associated pathways.
The SynAb™ platform allows for:
- Multiple epitope targeting to fully block critical functional domains of drug targets
- Super high affinity of antibody-antigen interactions for a greater therapeutic index
- Super-valent Ag-Ab complex ormation to facilitate faster clearance of drug targets
Fueled by on our proprietary H³ antibody discovery platform, SynAb™ technology is able to identify synergistic antibody combinations to many challenging targets.
Unique advantages of synergistic antibody combinations